FDA commissioner nominee questions do not address dietary supplement issues.
This article was originally published in The Tan Sheet
Executive Summary
PEDIATRIC INDICATIONS, CFC INHALERS AMONG OTC-RELATED ISSUES ADDRESSED in the list of questions forwarded by Senate Labor & Human Resources Committee Chairman James Jeffords (R-Vt.) to FDA Commissioner-nominee Jane Henney, MD, on July 31. The drug issues raised among the list of 140 questions posed in preparation for Henney's confirmation hearing focus almost exclusively on prescription concerns. However, there is overlap with OTCs on some issues, such as pediatric research requirements and the use of chlorofluorocarbons in metered-dose inhalers.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning